Author Of 1 Presentation
P0762 - What percentage of AQP4-Ab-negative NMOSD patients are MOG-Ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM) (ID 1033)
- E. Carnero Contentti
- P. Lopez
- J. Pettinicchi
- A. Pappolla
- J. Miguez
- L. Patrucco
- E. Cristiano
- C. Vrech
- V. Tkachuk
- S. Liwacki
- J. Correale
- M. Marrodan
- M. Gaitán
- M. Fiol
- L. Negrotto
- M. Ysrraelit
- M. Burgos
- F. Leguizamon
- D. Tavolini
- N. Deri
- M. Balbuena
- C. Mainella
- G. Luetic
- P. Blaya
- J. Hryb
- M. Menichini
- A. Alves Pinheiro
- P. Nofal
- G. Zanga
- A. Barboza
- I. Martos
- L. Lazaro
- E. Silva
- S. Bestoso
- M. Fracaro
- A. Carra
- O. Garcea
- N. Fernandez Liguori
- M. Alonso Serena
- A. Caride
- J. Rojas
Abstract
Background
Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) have been described in aquaporin-4-antibodies(AQP4-Ab)-negative neuromyelitis optica spectrum disorders (NMOSD) patients.
Objectives
We aimed to investigate the percentage of AQP4-Ab-negative NMOSD patients who are positive for MOG-Ab included in the Argentinean MS and NMOSD registry (RelevarEM, NCT 03375177).
Methods
RelevarEM is a longitudinal, strictly observational multiple sclerosis (MS) and NMOSD registry in Argentina. Epidemiological, serological test and neuroimaging (MRI) data from NMOSD were described.
Results
A total of 165 patients (79 AQP4-Ab positive, 67 AQP4-Ab negative and 19 unknown) were included. Of these, 155 patients fulfilled the 2015 NMOSD diagnostic criteria. Of 67 AQP4-Ab-negative patients, 36 were tested for MOG-Ab and 10 of them (31.8%) tested positive. Presence of relapses during the previous 6 months (40% vs. 12.9%), shorter disease duration (3.9 vs. 7.5 years), lower disability (2.3 vs. 3.4) and treatment duration (1.5 vs. 3.4 years) and both optic neuritis (90% vs. 44.5%) and optic nerve lesion on MRI (80% vs. 25.1%) were significantly associated with MOG-Ab-positive compared with NMOSD respectively
Conclusions
This is the first study of the longitudinal Argentinean registry of MS and NMOSD describing and comparing diseases that contributes to provide reliable real-world data in the country. We observed that 31.8% (10/36) of the AQP4-ab-negative patients tested for MOG-Ab were positive for this antibody, in line with results from other world regions.